

1 **Combined metagenomic- and culture-based approaches to investigate bacterial strain-level**  
2 **associations with medication-controlled mild-moderate atopic dermatitis**

3  
4 Nicole M Lane Starr<sup>a,b</sup>, Numan Al-Rayyan<sup>a</sup>, Jennifer M Smith<sup>a</sup>, Shelby Sandstrom<sup>b</sup>, Mary  
5 Hannah Swaney<sup>b</sup>, Rauf Salamzade<sup>b</sup>, Olivia Steidl<sup>a</sup>, Lindsay R Kalan<sup>b,c,d,\*</sup>, Anne Marie Singh<sup>a,b,e,\*</sup>

6  
7 <sup>a</sup> Department of Pediatrics, School of Medicine and Public Health, University of Wisconsin,  
8 Madison, WI, USA

9 <sup>b</sup> Department of Medical Microbiology and Immunology, School of Medicine and Public Health,  
10 University of Wisconsin, Madison, WI, USA

11 <sup>c</sup> Department of Medicine, Division of Infectious Disease, School of Medicine and Public  
12 Health, University of Wisconsin, Madison, WI, USA

13 <sup>d</sup> M.G. DeGroot Institute for Infectious Disease Research, David Braley Centre for Antibiotic  
14 Discovery, Department of Biochemistry and Biomedical Sciences, McMaster University,  
15 Hamilton, Ontario, Canada

16 <sup>e</sup> Department of Dermatology, School of Medicine and Public Health, University of Wisconsin,  
17 Madison, WI, USA

18  
19 \*Contributed equally

20  
21 **Corresponding Authors**

22 Anne Marie Singh, MD  
23 600 Highland Avenue  
24 Clinical Sciences Center K/9<sup>th</sup> Floor  
25 Madison, WI 53792  
26 Phone: 608-265-2605  
27 Email: [amsingh@wisc.edu](mailto:amsingh@wisc.edu)

28  
29 Lindsay Kalan, PhD  
30 Email: [kalanlr@mcmaster.ca](mailto:kalanlr@mcmaster.ca)

31  
32 **ABSTRACT**

33 **Background:** The skin microbiome is disrupted in atopic dermatitis (AD). Existing research  
34 focuses on moderate-severe, unmedicated disease.

35 **Objective:** Investigate metagenomic- and culture-based bacterial strain-level differences in mild,  
36 medicated AD, and the effects these have on human keratinocytes (HK).

37 **Methods:** Skin swabs from anterior forearms were collected from 20 pediatric participants; 11  
38 participants with AD sampled at lesional and nonlesional sites and 9 age- and sex-matched  
39 controls). Participants had primarily mild-moderate AD and maintained medication use. Samples  
40 were processed for microbial metagenomic sequencing and bacterial isolation. Isolates identified  
41 as *S. aureus* were tested for enterotoxin production. HK cultures were treated with cell free  
42 conditioned media from representative *Staphylococcus* species to measure barrier effects.

43 **Results:** Metagenomic sequencing identified significant differences in microbiome composition  
44 between AD and control groups. Differences were seen at the species- and strain-levels for  
45 *Staphylococci*, with *S. aureus* only found in AD participants and differences in *S. epidermidis*  
46 strains between control and AD swabs. These strains showed differences in toxin gene presence,

47 which was confirmed *in vitro* for *S. aureus* enterotoxins. The strain from the most severe AD  
48 participant produced enterotoxin B levels >100-fold higher than the other strains (p<0.001).  
49 Strains also displayed differential effects on HK metabolism and barrier function.  
50 **Conclusions:** Strain level differences in toxin genes from *Staphylococcus* strains may explain  
51 varying effects on HK, with *S. aureus* and *non-aureus* strains negatively impacting viability and  
52 barrier function. These differences are likely important in AD pathogenesis.

53

#### 54 **KEY MESSAGES**

- 55 • Staphylococcal strain effects, more so than species effects, impact keratinocyte barrier  
56 function and metabolism, suggesting that strain level differences, and not species-level,  
57 may be critical in AD pathogenesis.
- 58 • The microbiome from mild, medicated atopic dermatitis patients harbor *Staphylococcus*  
59 strains with detrimental effects on skin barrier, and may not only be mediated by *S.*  
60 *aureus*.

61

#### 62 **CAPSULE SUMMARY**

63 Patients with mild atopic dermatitis controlled by medication may still harbor strains of  
64 *Staphylococcus spp.* that carry toxins that negatively impact skin barrier function.

65

#### 66 **KEY WORDS**

67 Atopic dermatitis, skin microbiome, *Staphylococcus aureus*, *Staphylococcus epidermidis*,  
68 metagenomics, bacterial isolation, human keratinocytes

69

#### 70 **ABBREVIATIONS**

71 AD: atopic dermatitis

72 AMP: antimicrobial peptides

73 BHI: brain heart infusion

74 BHIT: brain heart infusion + 0.1% Tween 80

75 CFCM: cell free conditioned media

76 CoNS: coagulase negative Staphylococci

77 DM: differentiation media

78 HK: human keratinocyte(s)

79 MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide

80  $p_{adj}$  : adjusted p value (using Bonferroni)

81 SEB: staphylococcal enterotoxin B

82 ST: strain type

83 TEER: trans-epithelial electrical resistance

84

#### 85 **ACKNOWLEDGMENTS**

86 Our sincerest gratitude to the participants and their families who made this research possible. We  
87 would also like to thank members of both the Kalan and Singh labs for their valuable feedback  
88 during both the experimental and writing phases, especially J.Z. Alex Cheong and Elizabeth C.  
89 Townsend.

90

#### 91 **FUNDING**

92 NIAID K23-AI100995 (AMS)

93 University of Wisconsin School of Medicine and Public Health (AMS)

94 5T32AI007635-20 (NMLS)

95 NIAID U19AI142720 (LRK)

96 NIGMS R35GM137828 (LRK)

97

98 **DATA SUMMARY**

99 Genomic data is available on the National Center for Biotechnology Information (NCBI)  
100 database under BioProjects PRJNA830888.

101

102 **CONFLICTS OF INTEREST**

103 AMS serves on the Data Safety Monitoring Board for Siolta Therapeutics Inc and receives  
104 consulting fees from Incyte and Genentech.

105 LRK conducts research with the 3M company.

106 The other authors have no conflicts to declare.

107

108

109

110

## 111 **INTRODUCTION**

112 Atopic dermatitis (AD) is the most common inflammatory skin disease in children, with recent  
113 estimates suggesting as many as 1 in 5 children experience AD, with 80% exhibiting symptoms  
114 within the first 6 years of life<sup>1-3</sup>. AD is characterized by recurrent eczematous lesional skin sites.  
115 During flares, these erythematous patches are associated with pruritis, exudation, blistering, and  
116 lichenification, which can cause loss of sleep, poor mental health, and decreases in school/work  
117 performance<sup>1,5</sup>. It has been proposed that disruptions to the skin barrier during AD flares  
118 promote AD pathogenesis<sup>6,7</sup>. Numerous causes have been proposed for this disruption of the skin  
119 barrier, including genetic mutations (for example, in the filaggrin gene)<sup>8</sup>, immune dysregulation  
120 (classically characterized by Th2 and IgE predominance)<sup>4,6,7</sup>, environmental triggers (such as  
121 detergents and epicutaneous protease exposure)<sup>9-11</sup>, and alterations in the skin microbiome  
122 (particularly overgrowth of *Staphylococcus aureus*)<sup>12,13</sup>.

123  
124 The microbiota plays a critical role in the maturation and function of the skin barrier<sup>14</sup>, including  
125 pH balance<sup>15-17</sup>, water retention<sup>18</sup>, keratinocyte differentiation<sup>19,20</sup>, wound healing<sup>21-24</sup>, innate<sup>25,26</sup>  
126 and adaptive immune responses<sup>16,27,28</sup>, and pathogen competition<sup>29-31</sup>. Commensal skin bacteria,  
127 such as *Staphylococcus epidermidis*, produce antimicrobial peptides (AMPs) which are  
128 bactericidal and increase keratinocyte production of host AMPs<sup>29,32,33</sup>. These bacterial AMPs are  
129 active against *S. aureus* and are depleted on AD skin<sup>29</sup>. In contrast, *S. aureus* is important in AD  
130 pathogenesis. Multiple studies have shown an increased prevalence of *S. aureus* on the skin of  
131 AD patients, particularly on lesional sites<sup>34,35</sup>. *S. aureus* is known to produce a number of toxins,  
132 with staphylococcal enterotoxin B (SEB) in particular associated with more severe AD<sup>36,37</sup>.  
133 However, existing studies, including those associating increased *S. aureus* with lesional skin,  
134 have largely focused on moderate to severe participants while holding AD medications, and have  
135 focused on the microbiome at the genus and species levels. Whether *S. aureus* plays a similarly  
136 important role in less severe or well-controlled disease remains less well understood.  
137 Additionally, variability at the strain-level in AD progression is only beginning to be addressed,  
138 with early studies suggesting strains from severe AD subjects more negatively impact the skin in  
139 a murine model<sup>35,38</sup>.

## 141 **METHODS**

### 142 **Overall approach**

143 Skin swabs were collected from 20 participants aged 0.5-14 years for metagenomic analysis of the  
144 microbiome. When present, lesional samples were collected in addition to matched nonlesional  
145 samples. In contrast to prior studies, AD participants were primarily mild-moderate and  
146 continued use of topical therapies to control disease, mimicking real-world clinical scenarios.  
147 Shotgun metagenomic and culture-based approaches were used to evaluate the microbial  
148 communities associated with these samples. To determine the effects of strain variation on  
149 keratinocyte viability and barrier integrity, keratinocyte cultures were exposed to conditioned  
150 media containing secreted metabolites from select *Staphylococcus* isolates derived from  
151 participants with a range of clinical presentations.

### 153 **Patient recruitment and classification**

154 Recruitment occurred at the University of Wisconsin (UW)—Madison's Pediatric Allergy-  
155 Immunology and Dermatology clinics. Consent for the study and publication of results was  
156 obtained from participants' legal representatives. Approval was granted by the UW School of

157 Medicine and Public Health's Institutional Review Board. Participants were assigned non-  
158 identifying subject IDs for the study. Atopic dermatitis was defined as board certified pediatric  
159 allergist or pediatric dermatologist diagnosis with typical signs and symptoms of disease  
160 (eczematous dermatitis with typical morphology and distribution) using Hanifan and Reijka  
161 criteria. AD severity was determined as previously described using guidelines based criteria<sup>39</sup>.  
162 Age and sex matched controls were recruited if they had no current eczematous rash, no prior  
163 history of atopic dermatitis, and were not using any topical medication. See Supplemental  
164 Methods for criteria for other allergic disease classification.

165

### 166 **Sample collection**

167 Skin swabs were collected from 20 pediatric participants using standard Copan swabs for  
168 metagenomic analysis and eSwabs (Copan) to obtain live isolates. Lesional (if present) and  
169 nonlesional swabs were collected from all participants. See Supplemental Methods for full  
170 details.

171

### 172 **Metagenomic library preparation and analysis**

173 DNA extraction was done as previously described<sup>40</sup>. Samples were sent to University of  
174 Minnesota Genomics Center for library preparation and metagenomic sequencing. Resulting  
175 FASTQ files were processed using quality filtering, adapter removal, human decontamination,  
176 and tandem repeat removal as described previously<sup>40</sup>. Taxonomic classification and abundance  
177 estimation was performed using Kraken2 (v2.0.8-beta)<sup>41</sup> and Bracken (v2.5)<sup>42</sup>. Reads assigned as  
178 *Homo sapiens* or that were unclassified at the genus level were filtered out. Decontam (v1.16.0)  
179 was then used to identify and remove contaminant reads. See Supplemental Methods for  
180 additional details and Supplemental Figure 2 for read counts at each step. StrainGST (v1.3.3)<sup>43</sup>  
181 was used to infer the presence and relative abundance of specific *Staphylococcus* strains, using a  
182 set of 230 representative genomes from across the genus<sup>44</sup>. PubMLST was used to determine  
183 strain types (ST) for *S. epidermidis*<sup>45</sup>.

184

### 185 **Bacterial isolation and identification**

186 Single isolates were obtained through selective culturing on multiple media types, until single  
187 colonies were obtained. Sanger sequencing on the full-length 16S rRNA gene was used for  
188 taxonomic classification. See Supplemental Methods for full detail.

189

### 190 **Whole genome sequencing**

191 Bacteria identified as *Staphylococcus* were sent for whole genome sequencing at SeqCenter  
192 (Pittsburgh, PA) using the Illumina DNA Prep kit and IDT 10 bp UDI indices, with sequencing  
193 performed on an Illumina NextSeq 2000. Demultiplexing, quality control, and adapter trimming  
194 was done with bcl-convert (v3.9.3). These genomes were then used to generate a phylogenetic  
195 tree with autoMLST in the *de novo* mode and concatenated alignment functions<sup>46</sup>. The resulting  
196 tree was visualized using iTOL<sup>47</sup>. Gene-calling and standard-annotation was performed using  
197 PROKKA (v1.13)<sup>48</sup>. Toxin genes were identified through DIAMOND BLASTp alignment to the  
198 full Virulence Finder Database<sup>49</sup> download in Jan 2023, retaining the best hit per query based on  
199 bitscore with additional filters to retain only alignments exhibiting a maximum E-value of 1e-5, a  
200 minimum percent identity of 50%, and minimum query and subject coverages of 70%.

201

### 202 **Generation of staphylococcal cell free supernatants**

203 *Staphylococcus* isolates were grown from stock on trypticase soy agar overnight at 37 °C. Single  
204 colonies were then grown in trypticase soy broth overnight at 37 °C with shaking. The following  
205 morning, liquid cultures were used to inoculate 50 mL supplemented keratinocyte growth media  
206 (see Supplemental Methods for recipe) to a starting OD<sub>600</sub> of 0.1, followed by incubation at 37  
207 °C with shaking. OD<sub>600</sub> was read every 2 hr until an OD<sub>600</sub> of 0.7 was reached (range 0.693-  
208 1.156, average 0.774; typically 3-7 hrs). The cultures were centrifuged at 3220 x g for 10 min.  
209 The supernatants were collected and passed through a Watman cellulose Grade 1 filter paper (GE  
210 Healthcare Life Sciences), then through a 0.2 µm pore filter. Supernatants were stored at -20 °C  
211 until use. Cultures were serially diluted for CFU plating immediately following inoculation and  
212 immediately preceding collection to confirm similar CFUs across strains (average of 2.64 \*10<sup>9</sup>  
213 CFU/mL).

214

#### 215 ***In vitro* enterotoxin assay**

216 *Staphylococcus* isolates from stock were grown on BHI agar overnight at 37 °C. Single colonies  
217 were grown in 3 mL BHI liquid culture overnight at 37 °C with shaking. The next day, the  
218 cultures were centrifuged at 3500 x g for 5 min. The supernatants were collected and passed  
219 through a pore filter (0.2 µm). Enterotoxin levels were then measured using the BioPharm  
220 Ridascreen kit according to manufacturer's instructions.

221

#### 222 **MTT assay**

223 Effects of staphylococcal cell free supernatants on neonatal human keratinocyte (HK; American  
224 Type Culture Collection (ATCC; Manassas, Virginia)) cell viability were assessed using the 3-  
225 (4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric assay (Roche  
226 Diagnostics, Mannheim, Germany) per manufacturer instructions. See Supplemental Methods for  
227 full description.

228

#### 229 **TEER assay**

230 HKs were also used for the trans-epithelial electrical resistance (TEER) assay. The cells were  
231 cultured in HK media on a semipermeable filter insert in a 5% CO<sub>2</sub> atmosphere at 37 °C for 24  
232 hrs until they reached confluence. They were then switched to a differentiation medium (DM;  
233 DMEM medium supplemented with 1.8 mM calcium ion and 4 mM glutamine (Thermo Fisher  
234 Scientific)) alone (Control) or DM containing one of the *Staphylococcus* supernatants diluted to  
235 1\*10<sup>6</sup> CFU/mL. The integrity of the HK monolayer was verified by measuring the TEER assay  
236 after 2 days of treatment. Three independent replicates were used to calculate the results. The  
237 electrical resistance, measured in ohms, of an empty insert was subtracted from that of the insert  
238 with cells to yield the resistance of the cells. The electrical resistance was then multiplied by the  
239 area of the insert to determine the TEER. Results are expressed as the percentage change in  
240 TEER, which reflects the change in resistance after 2 days of treatment normalized to the TEER  
241 value of the control (DM alone).

242

#### 243 **Statistical analysis**

244 R (version 4.2.0) was used to do all analysis and figure generation. A Kruskal-Wallis test was  
245 used to compare select taxonomic levels and Shannon Diversity Index. PERMANOVA testing  
246 was used with Bray-Curtis dissimilarity estimates. These calculations were done on relative  
247 abundance set to 100% for microbes, bacteria, or *Staphylococcus*, where appropriate. A t-test  
248 was used to compare enterotoxin levels. Following a significant ANOVA, pairwise t-tests were

249 used to compare the MTT and TEER effects of the *Staphylococcus* isolates to media controls,  
250 with a Bonferroni correction used to account for multiple testing.

## 251 **RESULTS**

### 252 **Clinical characteristics and sample collection**

253 Twenty pediatric participants, aged 5 months to 14 years, were recruited from the University of  
254 Wisconsin Pediatric Allergy-Immunology and Dermatology Clinics (Table 1). One control  
255 participant was omitted due to having a parent-reported history of atopic dermatitis (AD) but no  
256 physician diagnosis and no symptoms of disease. The remaining participants consisted of 8  
257 healthy controls, and 11 with diagnosed AD, primarily mild-moderate in severity. Participants  
258 with AD were not asked to halt usage of topical treatments (Supplemental Table 1). Skin swabs  
259 collected from participants were classified as control, lesional, or nonlesional and were processed  
260 for DNA extraction and metagenomic analysis and untargeted bacterial isolation.

261

### 262 **Skin metagenomes from well-controlled AD participants resemble controls**

263 Metagenomic analysis of skin swabs was completed to provide a comprehensive view of the  
264 microbiome across participants. After filtering and quality control, the majority of reads (>97%)  
265 were identified as Bacteria (Fig 1A). The remaining 3% of reads mapped to either Eukaryota or  
266 Viral databases. The dominant bacterial genera were consistent with previous reports of pediatric  
267 skin—*Streptococcus*, *Cutibacterium*, *Micrococcus*, *Staphylococcus* (Figure 1B). Of note, the  
268 Eukaryota were dominated by *Malassezia restricta*, but there were no significant differences  
269 across genera (Supplemental Fig 3A). Interestingly, viral relative abundance was elevated in AD  
270 ( $p_{\text{adj}}=0.010$ ). This was likely driven by the presence of *Escherichia virus T4*, which was only  
271 identified in AD participants ( $p=0.004$ ) (Supplemental Fig 3B). Molluscum contagiosum virus,  
272 which is associated with skin infection, was also present on the skin of several participants, but  
273 was not significantly different among the groups (Supplemental Fig 3B).

274

275 Alpha (within-sample) diversity of the bacteria, as measured by the Shannon Diversity Index, did  
276 not significantly differ between the 3 groups (Figure 2A), nor when considering combined AD  
277 (pooled lesional and nonlesional samples) vs control samples. However, a trend emerged  
278 showing lower diversity but greater evenness in the lesional group compared to control  
279 (Supplemental Fig 4). A similar trend was noted with the combined AD group for evenness  
280 ( $p=0.07$ ). Similarly, beta (between-sample) diversity, measured by Bray-Curtis dissimilarity,  
281 showed weak grouping of controls vs combined AD ( $p=0.056$ ).

282

### 283 **Staphylococcal strain variation by AD status**

284 *Staphylococcus* species are amongst the most dominant taxa on human skin, and blooms of *S.*  
285 *aureus* have been associated with AD flares. Focusing on the *Staphylococcus* species within the  
286 metagenomes showed large intra-individual variability (Fig 3A). Although the proportion of  
287 *Staphylococcus* species present in the three groups did not significantly differ, the total number  
288 of different *Staphylococcus* species present in AD participants trended higher (Fig 3B;  $p=0.15$ ).  
289 Notably, we did find a decrease in Shannon Diversity when comparing combined AD vs control  
290 ( $p=0.048$ ; Fig 3C).

291

292 To determine if specific strains of Staphylococci vary by AD status, we classified the  
293 *Staphylococcus* strains in metagenomes using StrainGST<sup>43</sup>. This analysis showed a striking lack  
294 of *S. epidermidis* FDAARGOS\_1361 (strain type (ST) 153) in lesional samples, but was present

295 in 5/7 control samples and 4/8 of nonlesional samples (Fig 3D). Conversely, 3 other strains of *S.*  
296 *epidermidis* were present only in AD swabs (ST 5, 89, 387). These data suggest that the  
297 association of *S. epidermidis* with disease activity may be strain dependent. Using StrainGST, we  
298 observed *S. aureus* strains only in AD samples, specifically in the nonlesional swabs. Strains of  
299 *S. warneri* and *S. saprophyticus*, skin commensals that may act opportunistically<sup>50,51</sup>, were also  
300 only observed in AD samples (Fig 3D).

301

### 302 **Isolation and identification of live bacterial isolates**

303 To determine the role different strains may be playing in AD pathogenesis, we performed  
304 untargeted bacterial isolation. Using four different media to capture greater microbial diversity,  
305 601 isolates from 26 swabs were obtained. Full length 16S rRNA gene sequencing was used to  
306 taxonomically classify each isolate, resulting in the classification of 22 genera—13 among the  
307 305 isolates from control swabs, 10 from the 84 lesional isolates, and 14 from the 210  
308 nonlesional isolates (Supplemental Table 2). Of those, 93% were genera represented in the  
309 metagenomes. Actinobacteria were the most abundantly represented phylum, followed by  
310 Firmicutes and then Proteobacteria in both the metagenomic- and culture-based approaches. Of  
311 note, control swabs had >50% more isolates collected than from nonlesional swabs, which, in  
312 turn, had twice the number of isolates as lesional swabs. *Micrococcus* was the most abundantly  
313 cultured genera from control samples, while *Staphylococcus spp.* (specifically *aureus*, *capitis*,  
314 *epidermidis*, *hominis*, *saprophyticus*, *succinus*, and *warneri*) were the most abundantly isolated  
315 in lesional and nonlesional swabs (Supplemental Table 2). Combined, these two genera  
316 accounted for >40% of all isolates. Strikingly, the proportion of isolates that are *Staphylococcus*  
317 *spp.* rose greatly in the AD samples, particularly those from nonlesional sites.

318

### 319 **Toxins are elevated in AD-associated Staphylococci**

320 To better understand the role of Staphylococci strain-level differences on AD, we utilized the  
321 above-described isolate library. Staphylococci strains representing species isolated across  
322 participants were subject to whole genome sequencing. From this, a phylogenetic tree was  
323 generated showing relatedness of the selected strains (Figure 4A). Of note, all *S. aureus* isolates  
324 were collected from moderate and severe AD participants. Conversely, all *S. epidermidis* and *S.*  
325 *hominis* isolates were from mild AD or control participants. The *S. capitis* strains were split into  
326 2 clusters, one comprised of moderate-severe AD participants and the other associated with a  
327 single mild participant. Genes encoding toxin production in each genome were predicted using  
328 the Virulence Factor Database. We noted three patterns for genes encoding toxins—those  
329 universally present (not shown), those present in a specific species, and those present in only  
330 select isolates. All isolates, even coagulase negative Staphylococci (CoNS), contained at least  
331 five toxin-associated genes. As expected, *S. aureus* strains contained increased enterotoxin,  
332 hemolysin, and leukocidin genes (Fig 4B). Only 1/3 *S. aureus* strains isolated encoded for *seb*.  
333 This *S. aureus* strain, designated LK1493, was isolated from a participant recorded as having  
334 severe disease. To confirm the genomic predictions, the production of enterotoxins in each *S.*  
335 *aureus* isolate was tested *in vitro*, confirming high levels of SEB production by LK1493  
336 ( $p < 0.001$ ) (Fig 4C).

337

### 338 **Effects of *Staphylococcus* supernatants on keratinocytes *in vitro***

339 To test the *in vitro* effects of these differences on keratinocytes, cell free conditioned media  
340 (CFCM) derived from the *Staphylococcus* isolates were incubated with keratinocytes to



341 investigate cell viability and barrier integrity using MTT and TEER assays, respectively. Isolates  
342 from AD swabs significantly decreased cell viability (Fig 5A) and barrier function (Fig 5B).  
343 However, there was wide variability within each group.

344  
345 To investigate the variability within in each group, we first compared among species (Fig 5C,  
346 D). *S. hominis* species isolated from control swabs had no effect on cell viability, while *S.*  
347 *hominis* species from AD lesional swabs were detrimental. Indeed, many *Staphylococcus* species  
348 isolated from lesional swabs significantly impaired TEER ( $p_{\text{adj}} < 0.05$ ). We next examined each  
349 isolate (Fig 5E, F). We found intriguing differences driven by the strain of *Staphylococcus*  
350 tested. For example, *S. hominis* LK2134, isolated from a control participant, showed a trend  
351 towards improved barrier function ( $p_{\text{adj}} = 0.12$ ,  $p = 0.005$ ), whereas *S. hominis* LK2024, isolated  
352 from a lesional swab showed the most detrimental effect on barrier function ( $p_{\text{adj}} < 1E-10$ ). *S.*  
353 *warneri* LK1434 significantly decreased MTT ( $p_{\text{adj}} = 0.006$ ) but not TEER, whereas *S. warneri*  
354 LK1908 and LK2055 significantly decreased TEER ( $p_{\text{adj}} < 1E-4$ ) but not MTT. None of the *S.*  
355 *epidermidis* isolates significantly impacted MTT, although 2 decreased TEER ( $p_{\text{adj}} < 0.001$ ). All  
356 isolates of *S. capitis* significantly decreased TEER ( $p_{\text{adj}} < 0.005$ ), but only 1 trended towards a  
357 decrease in MTT ( $p_{\text{adj}} = 0.060$ ). Similarly, 2 strains of *S. aureus* significantly decreased TEER  
358 ( $p_{\text{adj}} < 1E-4$ ), while the third trended towards a decrease in MTT ( $p_{\text{adj}} = 0.14$ ).

359  
360

361 **DISCUSSION**

362 The skin microbiome is critical in maintaining proper functioning of the skin barrier, and  
363 previous research has focused on the role of *S. aureus* in moderate-severe AD while medications  
364 are held. In this setting, the relative abundance of *S. aureus* has been shown to increase during  
365 acute disease flares<sup>12,13</sup>. In addition, *S. aureus* has also been shown to produce toxins,  
366 particularly SEB, which are associated with more severe disease<sup>36,37</sup>. However, there is limited  
367 research into medication-controlled AD, which is more reflective of the clinical setting.

368  
369 In our medicated cohort, we did not observe the emergence *S. aureus* blooms reported in  
370 previous studies enrolling unmedicated AD, even in lesional samples. When *S. aureus* was  
371 detected, it was primarily identified from nonlesional AD swabs. This is similar to a previous  
372 study that found mitigation of *S. aureus* overgrowth when taking medication<sup>13</sup>. As topical  
373 corticosteroids have been shown to decrease *S. aureus* bioburden<sup>52</sup>, our data together with the  
374 previous work, suggests that the interventions to manage AD are decreasing *S. aureus*  
375 overgrowth, despite disease flares.

376  
377 Differences in *Staphylococcus* strains were present, including in CoNS. A strain of *S.*  
378 *epidermidis* (ST153) was primarily associated with healthy participants. This strain was also  
379 associated with healthy volunteers in a study of catheter-related bacteremia<sup>53</sup>. Conversely,  
380 metagenomes from AD lesions contained number of other *S. epidermidis* strains. Although  
381 previous studies in AD have suggested potential protective effects of *S. epidermidis*, it can  
382 behave as an opportunistic pathogen. The pathogenicity of *S. epidermidis* seems to vary greatly  
383 by strain, with certain strains being associated with health and others with disease<sup>35,54,55</sup>. Thus,  
384 these data suggest the importance of strain-level differences in both *S. aureus* and non-aureus  
385 *Staphylococcus* species in AD disease expression and severity.

386  
387 In addition, we observed marked differences in toxin gene presence across the Staphylococcal  
388 isolates. All 3 *S. aureus* strains, isolated from moderate and severe participants, encoded for  
389 more toxin genes than other strains. One *S. aureus* strain (isolated from a severe patient),  
390 contained the *seb* gene and expressed this protein at high levels *in vitro*. Previous studies have  
391 suggested SEB is associated with more severe AD<sup>36,37</sup>, likely due to its cytotoxic effects which  
392 disrupt barrier function<sup>56</sup>.

393  
394 Importantly, our data evaluating keratinocyte metabolism and barrier function after exposure to  
395 secreted factors from diverse Staphylococci species demonstrates that many Staphylococcal  
396 strains are capable of disrupting keratinocyte function, even in the absence of enterotoxin  
397 production. Additionally, keratinocyte dysfunction occurred across several species, and was  
398 strain dependent. In general, *S. aureus* and *S. capitis* were associated with deleterious effects on  
399 barrier function, while *S. epidermidis* and *S. warneri* had strain-level varied impacts as measured  
400 by TEER. Finally, different strains of *S. hominis* induced opposing effects on keratinocyte  
401 integrity as measured by MTT. Ongoing research will attempt to clarify the drivers of these  
402 differential effects.

403  
404 Taken together, our data underscore the importance of bacterial strain in AD disease expression  
405 and pathogenesis, and suggest that topical steroids can be effective in controlling *S. aureus*  
406 overgrowth. It is worth noting that this was a small cross-sectional study, with participants

407 covering a range of developmental stages. The skin microbiome can change significantly from  
408 infancy through puberty<sup>60</sup>, and controls were age and sex matched to help address this issue.  
409 Additionally, medications used varied somewhat among participants, which may have  
410 differential impacts on the skin microbiome. Thus, future research will add additional  
411 participants to clarify these effects, and to collect additional strains of *Staphylococcus*, as well as  
412 expanding to genera beyond *Staphylococcus*.

413  
414 The data presented demonstrate the critical role of strain-level differences in AD pathogenicity.  
415 Strains differed with regard to presence and amount of toxins expressed, effect on keratinocyte  
416 viability and barrier function. Additionally, deleterious effects were not exclusive to *S. aureus*.  
417 Thus, both inter- and intra-species differences impact AD pathogenesis, suggesting that strain-  
418 level differences are important considerations in AD pathogenesis and disease expression.

419  
420  
421  
422

423 **REFERENCES**

- 424 1. Williams H, Robertson C, Stewart A, Ait-Khaled N, Anabwani G, Anderson R, et al. Worldwide  
425 variations in the prevalence of symptoms of atopic eczema in the international study of asthma and  
426 allergies in childhood. *Journal of Allergy and Clinical Immunology* [Internet]. 1999 [cited 2023  
427 Jan 27];103:125–38. Available from:  
428 <http://www.jacionline.org/article/S0091674999705361/fulltext>
- 429 2. Mohn CH, Blix HS, Halvorsen JA, Nafstad P, Valberg M, Lagerløv P. Incidence Trends of Atopic  
430 Dermatitis in Infancy and Early Childhood in a Nationwide Prescription Registry Study in  
431 Norway. *JAMA Netw Open* [Internet]. 2018 [cited 2023 Jan 27];1. Available from:  
432 [/pmc/articles/PMC6324394/](https://pubmed.ncbi.nlm.nih.gov/3124394/)
- 433 3. Perkin MR, Strachan DP, Williams HC, Kennedy CTC, Golding J. Natural history of atopic  
434 dermatitis and its relationship to serum total immunoglobulin E in a population-based birth cohort  
435 study. *Pediatric Allergy and Immunology* [Internet]. 2004 [cited 2023 Jan 28];15:221–9. Available  
436 from: <https://onlinelibrary.wiley.com/doi/full/10.1111/j.1399-3038.2004.00160.x>
- 437 4. Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. *Nature Reviews*  
438 *Disease Primers* 2018 4:1 [Internet]. 2018 [cited 2023 Jan 27];4:1–20. Available from:  
439 <https://www.nature.com/articles/s41572-018-0001-z>
- 440 5. Odhiambo JA, Williams HC, Clayton TO, Robertson CF, Asher MI, Ait-Khaled N, et al. Global  
441 variations in prevalence of eczema symptoms in children from ISAAC Phase Three. *Journal of*  
442 *Allergy and Clinical Immunology* [Internet]. 2009 [cited 2023 Jan 27];124:1251-1258.e23.  
443 Available from: <http://www.jacionline.org/article/S0091674909015358/fulltext>
- 444 6. Spergel JM, Mizoguchi E, Brewer JP, Martin TR, Bhan AK, Geha RS. Epicutaneous sensitization  
445 with protein antigen induces localized allergic dermatitis and hyperresponsiveness to methacholine  
446 after single exposure to aerosolized antigen in mice. *J Clin Invest* [Internet]. 1998 [cited 2023 Jan  
447 27];101:1614–22. Available from: <http://www.jci.org>
- 448 7. Tran MM, Lefebvre DL, Dharma C, Dai D, Lou WYW, Subbarao P, et al. Predicting the atopic  
449 march: Results from the Canadian Healthy Infant Longitudinal Development Study. *Journal of*  
450 *Allergy and Clinical Immunology* [Internet]. 2018 [cited 2023 Jan 27];141:601-607.e8. Available  
451 from: <http://www.jacionline.org/article/S009167491731480X/fulltext>
- 452 8. Drislane C, Irvine AD. The role of filaggrin in atopic dermatitis and allergic disease. *Annals of*  
453 *Allergy, Asthma & Immunology* [Internet]. 2020 [cited 2023 Jan 28];124:36–43. Available from:  
454 <http://www.annallergy.org/article/S108112061931289X/fulltext>
- 455 9. Moreno AS, Mcphee R, Arruda LK, Howell MD. Targeting the T Helper 2 Inflammatory Axis in  
456 Atopic Dermatitis. *Int Arch Allergy Immunol* [Internet]. 2016 [cited 2023 Jan 28];171:71–80.  
457 Available from: <https://pubmed.ncbi.nlm.nih.gov/27846627/>
- 458 10. Xian M, Wawrzyniak P, Rückert B, Duan S, Meng Y, Sokolowska M, et al. Anionic surfactants  
459 and commercial detergents decrease tight junction barrier integrity in human keratinocytes. *J*  
460 *Allergy Clin Immunol* [Internet]. 2016 [cited 2023 Feb 12];138:890-893.e9. Available from:  
461 <https://pubmed.ncbi.nlm.nih.gov/27596709/>
- 462 11. Celebi Sözener Z, Cevhertas L, Nadeau K, Akdis M, Akdis CA. Environmental factors in  
463 epithelial barrier dysfunction. *J Allergy Clin Immunol* [Internet]. 2020 [cited 2023 Feb  
464 12];145:1517–28. Available from: <https://pubmed.ncbi.nlm.nih.gov/32507229/>
- 465 12. Geoghegan JA, Irvine AD, Foster TJ. *Staphylococcus aureus* and Atopic Dermatitis: A Complex  
466 and Evolving Relationship. Vol. 26, *Trends in Microbiology*. Elsevier Ltd; 2018. p. 484–97.

- 467 13. Kong HH, Oh J, Deming C, Conlan S, Grice EA, Beatson MA, et al. Temporal shifts in the skin  
468 microbiome associated with disease flares and treatment in children with atopic dermatitis.  
469 Genome Res [Internet]. 2012 [cited 2020 Jul 6];22:850–9. Available from:  
470 /pmc/articles/PMC3337431/?report=abstract
- 471 14. Harris-Tryon TA, Grice EA. Microbiota and maintenance of skin barrier function. Science (1979)  
472 [Internet]. 2022 [cited 2023 Jan 27];376:940–5. Available from:  
473 <https://www.science.org/doi/10.1126/science.abo0693>
- 474 15. Bomar L, Brugger SD, Yost BH, Davies SS, Lemon KP. Corynebacterium accolens Releases  
475 Antipneumococcal Free Fatty Acids from Human Nostril and Skin Surface Triacylglycerols. mBio  
476 [Internet]. 2016 [cited 2023 Jan 28];7. Available from: /pmc/articles/PMC4725001/  
477 16. Ridaura VK, Bouladoux N, Claesen J, Erin Chen Y, Byrd AL, Constantinides MG, et al.  
478 Contextual control of skin immunity and inflammation by Corynebacterium. Journal of  
479 Experimental Medicine [Internet]. 2018 [cited 2020 Jul 1];215:785–99. Available from:  
480 /pmc/articles/PMC5839758/?report=abstract
- 481 17. Nakatsuji T, Kao MC, Zhang L, Zouboulis CC, Gallo RL, Huang CM. Sebum free fatty acids  
482 enhance the innate immune defense of human sebocytes by upregulating  $\beta$ -defensin-2 expression.  
483 Journal of Investigative Dermatology [Internet]. 2010 [cited 2020 Jul 16];130:985–94. Available  
484 from: /pmc/articles/PMC3057125/?report=abstract
- 485 18. Nodake Y, Matsumoto S, Miura R, Honda H, Ishibashi G, Matsumoto S, et al. Pilot study on novel  
486 skin care method by augmentation with Staphylococcus epidermidis, an autologous skin microbe -  
487 A blinded randomized clinical trial. J Dermatol Sci [Internet]. 2015 [cited 2023 Jan 27];79:119–  
488 26. Available from: <http://www.jdsjournal.com/article/S0923181115001668/fulltext>
- 489 19. Uberoi A, Bartow-McKenney C, Zheng Q, Flowers L, Campbell A, Knight SAB, et al.  
490 Commensal Microbiota Regulates Skin Barrier Function And Repair Via Signaling Through The  
491 Aryl Hydrocarbon Receptor. Cell Host Microbe [Internet]. 2021 [cited 2023 Jan 28];29:1235.  
492 Available from: /pmc/articles/PMC8364505/  
493 20. Zheng Y, Hunt RL, Villaruz AE, Fisher EL, Liu R, Liu Q, et al. Commensal Staphylococcus  
494 epidermidis contributes to skin barrier homeostasis by generating protective ceramides. Cell Host  
495 Microbe [Internet]. 2022 [cited 2023 Jan 28];30:301-313.e9. Available from:  
496 <http://www.cell.com/article/S1931312822000403/fulltext>
- 497 21. Kalan LR, Meisel JS, Loesche MA, Horwinski J, Soaita I, Chen X, et al. Strain- and Species-Level  
498 Variation in the Microbiome of Diabetic Wounds Is Associated with Clinical Outcomes and  
499 Therapeutic Efficacy. Cell Host Microbe [Internet]. 2019 [cited 2020 Jul 2];25:641-655.e5.  
500 Available from: /pmc/articles/PMC6526540/?report=abstract
- 501 22. di Domizio J, Belkhodja C, Chenuet P, Fries A, Murray T, Mondéjar PM, et al. The commensal  
502 skin microbiota triggers type I IFN–dependent innate repair responses in injured skin. Nature  
503 Immunology 2020 21:9 [Internet]. 2020 [cited 2023 Jan 28];21:1034–45. Available from:  
504 <https://www.nature.com/articles/s41590-020-0721-6>
- 505 23. Ubags ND, Trompette A, Pernot J, Nibbering B, Wong NC, Pattaroni C, et al. Microbiome-  
506 induced antigen-presenting cell recruitment coordinates skin and lung allergic inflammation.  
507 Journal of Allergy and Clinical Immunology [Internet]. 2021 [cited 2023 Jan 28];147:1049-  
508 1062.e7. Available from: <http://www.jacionline.org/article/S0091674920309611/fulltext>

- 509 24. Wang G, Sweren E, Liu H, Wier E, Alphonse MP, Chen R, et al. Bacteria Induce Skin  
510 Regeneration via IL-1 $\beta$  Signaling. *Cell Host Microbe* [Internet]. 2021 [cited 2023 Jan 28];29:777.  
511 Available from: [/pmc/articles/PMC8122070/](https://pubmed.ncbi.nlm.nih.gov/34812207/)
- 512 25. Sanford JA, Zhang LJ, Williams MR, Gangoi JA, Huang CM, Gallo RL. Inhibition of HDAC8  
513 and HDAC9 by microbial short-chain fatty acids breaks immune tolerance of the epidermis to  
514 TLR ligands. *Sci Immunol* [Internet]. 2016 [cited 2020 Jul 6];1. Available from:  
515 <https://immunology.sciencemag.org/content/1/4/eaah4609>
- 516 26. Sanford JA, O'Neill AM, Zouboulis CC, Gallo RL. Short-chain fatty acids from *Cutibacterium*  
517 *acnes* activate both a canonical and epigenetic inflammatory response in human sebocytes. *J*  
518 *Immunol* [Internet]. 2019 [cited 2023 Jan 28];202:1767. Available from:  
519 [/pmc/articles/PMC7251550/](https://pubmed.ncbi.nlm.nih.gov/31251550/)
- 520 27. Constantinides MG, Link VM, Tamoutounour S, Wong AC, Perez-Chaparro PJ, Han SJ, et al.  
521 MAIT cells are imprinted by the microbiota in early life and promote tissue repair. *Science*  
522 [Internet]. 2019 [cited 2023 Jan 28];366. Available from: [/pmc/articles/PMC7603427/](https://pubmed.ncbi.nlm.nih.gov/33427/)
- 523 28. Legoux F, Bellet D, Daviaud C, el Morr Y, Darbois A, Niort K, et al. Microbial metabolites  
524 control the thymic development of mucosal-associated invariant T cells. *Science (1979)* [Internet].  
525 2019 [cited 2023 Jan 28];366:494–9. Available from:  
526 <https://www.science.org/doi/10.1126/science.aaw2719>
- 527 29. Nakatsuji T, Chen TH, Narala S, Chun KA, Two AM, Yun T, et al. Antimicrobials from human  
528 skin commensal bacteria protect against *Staphylococcus aureus* and are deficient in atopic  
529 dermatitis. *Sci Transl Med* [Internet]. 2017 [cited 2020 Jul 1];9:4680. Available from:  
530 [/pmc/articles/PMC5600545/?report=abstract](https://pubmed.ncbi.nlm.nih.gov/284545/)
- 531 30. Bitschar K, Sauer B, Focken J, Dehmer H, Moos S, Konnerth M, et al. *Lugdunin* amplifies innate  
532 immune responses in the skin in synergy with host- and microbiota-derived factors. *Nat Commun*  
533 [Internet]. 2019 [cited 2020 Jul 13];10. Available from: [https://doi.org/10.1038/s41467-019-](https://doi.org/10.1038/s41467-019-10646-7)  
534 [10646-7](https://doi.org/10.1038/s41467-019-10646-7)
- 535 31. Claesen J, Spagnolo JB, Ramos SF, Kurita KL, Byrd AL, Aksenov AA, et al. A *Cutibacterium*  
536 *acnes* antibiotic modulates human skin microbiota composition in hair follicles. *Sci Transl Med*  
537 [Internet]. 2020 [cited 2023 Jan 28];12. Available from: [/pmc/articles/PMC8478231/](https://pubmed.ncbi.nlm.nih.gov/3478231/)
- 538 32. Braff MH, Bardan A, Nizet V, Gallo RL. Cutaneous defense mechanisms by antimicrobial  
539 peptides. *Journal of Investigative Dermatology* [Internet]. 2005 [cited 2020 Jul 20];125:9–13.  
540 Available from: <http://www.jidonline.org/article/S0022202X1532340X/fulltext>
- 541 33. Lai Y, Cogen AL, Radek KA, Park HJ, MacLeod DT, Leichtle A, et al. Activation of TLR2 by a  
542 small molecule produced by *staphylococcus epidermidis* increases antimicrobial defense against  
543 bacterial skin infections. *Journal of Investigative Dermatology* [Internet]. 2010 [cited 2020 Jul  
544 9];130:2211–21. Available from: <https://pubmed.ncbi.nlm.nih.gov/20463690/>
- 545 34. Leyden JJ, Marples RR, Kligman AM. *Staphylococcus aureus* in the lesions of atopic dermatitis.  
546 *British Journal of Dermatology* [Internet]. 1974 [cited 2020 Jul 9];90:525–525. Available from:  
547 <http://doi.wiley.com/10.1111/j.1365-2133.1974.tb06447.x>
- 548 35. Byrd AL, Deming C, Cassidy SKB, Harrison OJ, Ng WI, Conlan S, et al. *Staphylococcus aureus*  
549 and *Staphylococcus epidermidis* strain diversity underlying pediatric atopic dermatitis. *Sci Transl*  
550 *Med* [Internet]. 2017 [cited 2020 Jul 8];9. Available from:  
551 [/pmc/articles/PMC5706545/?report=abstract](https://pubmed.ncbi.nlm.nih.gov/284545/)

- 552 36. Strange P, Skov L, Lisby S, Nielsen PL, Baadsgaard O. Staphylococcal Enterotoxin B Applied on  
553 Intact Normal and Intact Atopic Skin Induces Dermatitis. *Arch Dermatol* [Internet]. 1996 [cited  
554 2023 Jan 28];132:27–33. Available from:  
555 <https://jamanetwork.com/journals/jamadermatology/fullarticle/557399>
- 556 37. Breuer K, Kapp A, Werfel T. Bacterial infections and atopic dermatitis. *Allergy* [Internet]. 2001  
557 [cited 2023 Jan 28];56:1034–41. Available from:  
558 <https://onlinelibrary.wiley.com/doi/full/10.1034/j.1398-9995.2001.00146.x>
- 559 38. Iwamoto K, Moriwaki M, Miyake R, Hide M. Staphylococcus aureus in atopic dermatitis: Strain-  
560 specific cell wall proteins and skin immunity. Vol. 68, *Allergology International*. Japanese Society  
561 of Allergology; 2019. p. 309–15.
- 562 39. Li JC, Arkin LM, Makhija MM, Singh AM. Prevalence of food allergy diagnosis in pediatric  
563 patients with atopic dermatitis referred to allergy and/or dermatology subspecialty clinics. *Journal*  
564 *of Allergy and Clinical Immunology: In Practice* [Internet]. 2022 [cited 2023 Jan 27];10:2469–71.  
565 Available from: <http://www.jaci-inpractice.org/article/S2213219822005773/fulltext>
- 566 40. Swaney MH, Sandstrom S, Kalan LR. Cobamide Sharing Is Predicted in the Human Skin  
567 Microbiome. *mSystems* [Internet]. 2022 [cited 2023 Jan 28];7. Available from:  
568 </pmc/articles/PMC9600381/>
- 569 41. Wood DE, Lu J, Langmead B. Improved metagenomic analysis with Kraken 2. *Genome Biol*  
570 [Internet]. 2019 [cited 2023 Jan 28];20. Available from: </pmc/articles/PMC6883579/>
- 571 42. Lu J, Breitwieser FP, Thielen P, Salzberg SL. Bracken: Estimating species abundance in  
572 metagenomics data. *PeerJ Comput Sci* [Internet]. 2017 [cited 2023 Jan 28];2017:e104. Available  
573 from: <https://peerj.com/articles/cs-104>
- 574 43. van Dijk LR, Walker BJ, Straub TJ, Worby CJ, Grote A, Schreiber HL, et al. StrainGE: a toolkit to  
575 track and characterize low-abundance strains in complex microbial communities. *Genome Biol*  
576 [Internet]. 2022 [cited 2023 Jan 28];23. Available from: </pmc/articles/PMC8900328/>
- 577 44. Salamzade R, Cheong JZA, Sandstrom S, Swaney MH, Stubbendieck RM, Starr NL, et al.  
578 Evolutionary investigations of the biosynthetic diversity in the skin microbiome using IsaBGC.  
579 *bioRxiv* [Internet]. 2022 [cited 2023 Feb 13];2022.04.20.488953. Available from:  
580 <https://www.biorxiv.org/content/10.1101/2022.04.20.488953v3>
- 581 45. Jolley KA, Bray JE, Maiden MCJ. Open-access bacterial population genomics: BIGSdb software,  
582 the PubMLST.org website and their applications. *Wellcome Open Res* [Internet]. 2018 [cited 2023  
583 Feb 12];3. Available from: <https://pubmed.ncbi.nlm.nih.gov/30345391/>
- 584 46. Alanjary M, Steinke K, Ziemert N. AutoMLST: an automated web server for generating multi-  
585 locus species trees highlighting natural product potential. *Nucleic Acids Res* [Internet]. 2019 [cited  
586 2023 Jan 28];47:W276. Available from: </pmc/articles/PMC6602446/>
- 587 47. Letunic I, Bork P. Interactive Tree Of Life (iTOL) v5: an online tool for phylogenetic tree display  
588 and annotation. *Nucleic Acids Res* [Internet]. 2021 [cited 2023 Jan 28];49:W293–6. Available  
589 from: <https://academic.oup.com/nar/article/49/W1/W293/6246398>
- 590 48. Seemann T. Prokka: rapid prokaryotic genome annotation. *Bioinformatics* [Internet]. 2014 [cited  
591 2023 Jan 28];30:2068–9. Available from:  
592 <https://academic.oup.com/bioinformatics/article/30/14/2068/2390517>
- 593 49. Chen L, Yang J, Yu J, Yao Z, Sun L, Shen Y, et al. VFDB: a reference database for bacterial  
594 virulence factors. *Nucleic Acids Res* [Internet]. 2005 [cited 2023 Jan 28];33:D325. Available  
595 from: </pmc/articles/PMC539962/>

- 596 50. Kanuparth A, Challa T, Meegada S, Siddamreddy S, Muppidi V. *Staphylococcus warneri*: Skin  
597 Commensal and a Rare Cause of Urinary Tract Infection. *Cureus*. 2020;
- 598 51. Silva KCS, Silva LOS, Silva GAA, Borges CL, Novaes E, PACEZ JD, et al. *Staphylococcus*  
599 *saprophyticus* proteomic analyses elucidate differences in the protein repertoires among clinical  
600 strains related to virulence and persistence. *Pathogens*. 2020;9.
- 601 52. Nørreslet LB, Edslev SM, Bregnhøj A, Sommerlund M, Ebbenhøj NE, Andersen PS, et al. Topical  
602 corticosteroids reduce the density of *Staphylococcus aureus* in hand eczema. *Journal of the*  
603 *European Academy of Dermatology & Venereology*. 2022;36:e318–9.
- 604 53. Cherifi S, Byl B, Deplano A, Nonhoff C, Denis O, Hallin M. Comparative Epidemiology of  
605 *Staphylococcus epidermidis* Isolates from Patients with Catheter-Related Bacteremia and from  
606 Healthy Volunteers. *J Clin Microbiol [Internet]*. 2013 [cited 2023 Feb 12];51:1541. Available  
607 from: [/pmc/articles/PMC3647944/](https://pubmed.ncbi.nlm.nih.gov/23647944/)
- 608 54. Méric G, Mageiros L, Pensar J, Laabei M, Yahara K, Pascoe B, et al. Disease-associated  
609 genotypes of the commensal skin bacterium *Staphylococcus epidermidis*. *Nat Commun [Internet]*.  
610 2018 [cited 2020 Jul 27];9:1–11. Available from: [www.nature.com/naturecommunications](https://www.nature.com/naturecommunications)
- 611 55. Conlan S, Mijares LA, Becker J, Blakesley RW, Bouffard GG, Brooks S, et al. *Staphylococcus*  
612 *epidermidis* pan-genome sequence analysis reveals diversity of skin commensal and hospital  
613 infection-associated isolates. *Genome Biol [Internet]*. 2012 [cited 2020 Jul 8];13:R64. Available  
614 from: [/pmc/articles/PMC4053731/?report=abstract](https://pubmed.ncbi.nlm.nih.gov/224053731/)
- 615 56. Campbell WN, Fitzpatrick M, Ding X, Jett M, Gemski P, Goldblum SE, et al. SEB is cytotoxic  
616 and alters EC barrier function through protein tyrosine phosphorylation in vitro. 1997.
- 617 57. Severn MM, Williams MR, Shahbandi A, Bunch ZL, Lyon LM, Nguyen A, et al. The Ubiquitous  
618 Human Skin Commensal *Staphylococcus hominis* Protects against Opportunistic Pathogens.  
619 *mBio*. 2022;13.
- 620 58. Vasconcellos D, Weng B, Wu P, Thompson G, Sutjita M. *Staphylococcus hominis* Infective  
621 Endocarditis Presenting with Embolic Splenic and Renal Infarcts and Spinal Discitis. *Case Rep*  
622 *Infect Dis*. 2022;2022:1–5.
- 623 59. Kuipers A, Stapels DAC, Weerwind LT, Ko YP, Ruyken M, Lee JC, et al. The *Staphylococcus*  
624 *aureus* polysaccharide capsule and Efb-dependent fibrinogen shield act in concert to protect  
625 against phagocytosis. *Microbiology (United Kingdom)*. 2016;162:1185–94.
- 626 60. Townsend EC, Kalan LR. The dynamic balance of the skin microbiome across the lifespan. 2023  
627 [cited 2023 Jan 27]; Available from: [http://portlandpress.com/biochemsoctrans/article-](http://portlandpress.com/biochemsoctrans/article-pdf/doi/10.1042/BST20220216/941724/bst-2022-0216c.pdf)  
628 [pdf/doi/10.1042/BST20220216/941724/bst-2022-0216c.pdf](https://doi.org/10.1042/BST20220216/941724/bst-2022-0216c.pdf)
- 629 61. Prince BT, Devonshire AL, Erickson KA, Bergerson J, Fuleihan D, Szychlinski C, et al.  
630 Regulatory T-cell populations in children are affected by age and food allergy diagnosis. *J Allergy*  
631 *Clin Immunol [Internet]*. 2017 [cited 2023 Feb 12];140:1194–1196.e16. Available from:  
632 <https://pubmed.ncbi.nlm.nih.gov/28549988/>
- 633 62. COVE JH, HOLLAND KT, COUNLIFFE WJ. The Vitamin Requirements of *Staphylococci*  
634 Isolated from Human Skin. *Journal of Applied Bacteriology [Internet]*. 1980 [cited 2023 Feb  
635 13];49:29–37. Available from: [https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-](https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2672.1980.tb01041.x)  
636 [2672.1980.tb01041.x](https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2672.1980.tb01041.x)
- 637 63. Machado H, Weng LL, Dillon N, Seif Y, Holland M, Pekar JE, et al. Strain-Specific Metabolic  
638 Requirements Revealed by a Defined Minimal Medium for Systems Analyses of *Staphylococcus*



639 aureus. Appl Environ Microbiol [Internet]. 2019 [cited 2023 Feb 13];85. Available from:  
640 <https://pubmed.ncbi.nlm.nih.gov/31471305/>  
641 64. Saheb Kashaf S, Proctor DM, Deming C, Saary P, Hölzer M, Mullikin J, et al. Integrating  
642 cultivation and metagenomics for a multi-kingdom view of skin microbiome diversity and  
643 functions. Nat Microbiol [Internet]. 2022 [cited 2023 Jan 28];7:169. Available from:  
644 </pmc/articles/PMC8732310/>  
645  
646

647 **TABLE 1**  
648 Demographic data for the participants.  
649

<b>PARTICIPANTS</b>	<b>N (% of total)</b>
Total	19 (100%)
Female	8 (42.11%)
<b>AGE</b>	<b>Years</b>
Range	0.46 - 14.02
Median (IQR)	3.07 (1.74 – 6.82)
<b>RACE</b>	
Asian	2 (10.53%)
Black or African American	2 (10.53%)
Other	1 (5.26%)
White	14 (73.68%)
<b>AD SEVERITY</b>	
None	8 (42.11%)
Mild	7 (36.84%)
Moderate	2 (10.53%)
Severe	2 (10.53%)

650  
651  
652

653 **FIGURE LEGENDS**

654

655 **FIGURE 1—Metagenomic analysis of skin swabs from AD and control groups**

656 Bar graphs of the relative abundances of kingdom-level data (A), with an inset to show  
657 differences in Eukaryota and Viruses. Relative abundance plot of bacterial genera (B), with hue  
658 corresponding to phylum, genera are ordered by phylum abundance. For both, each swab was  
659 normalized to 100% relative abundance of all included taxa along the y-axis and bars are  
660 grouped by AD status then ordered by age along the x-axis.

661

662 **FIGURE 2—Diversity metrics did not differ significantly by AD status**

663 The Shannon Diversity Index (A) and Bray Curtis Dissimilarity (B) were calculated for all  
664 metagenomes and then grouped by AD Status.

665

666 **FIGURE 3—*Staphylococcus* species and strain level variation by AD status**

667 (A) Bar chart showing relative abundances of *Staphylococcus* species detected in each  
668 metagenome, grouped by AD status, ordered by age across the x-axis. (B) Bar chart showing the  
669 relative abundances of the top 5 *Staphylococcus* species (as called by Kraken/Braken), grouped  
670 by AD status. (C) Shannon diversity index of all *Staphylococcus* species (as called by  
671 Kraken/Braken), grouped by AD Status. (D) *Staphylococcus* strains (as called by StrainGST),  
672 grouped by AD status, ordered by age.

673

674 **FIGURE 4—Toxins are elevated in AD-associated *Staphylococci***

675 (A) Phylogenetic tree of select cultured *Staphylococcus* strains. Sequenced whole genomes were  
676 uploaded to autoMLST using de novo mode and concatenated alignment function. The resulting  
677 tree was annotated with iTOL. Type strains are colored by species. Cultured strains are in black,  
678 with # symbol indicating subject's AD severity (none: control, #: mild AD, ##: moderate AD,  
679 ####: severe AD). (B) Heat map indicating presence of toxin genes observed in the whole genome  
680 sequences of those same selected *Staphylococcus* strains, as called by PROKKA. (C) In vitro  
681 enterotoxin levels in the 3 putatively unique *S. aureus* strains show strain-level differences, with  
682 SE levels increasing with severity. Bar graph depict mean and se; subject label color denotes AD  
683 severity; line represents positivity threshold.

684

685 **FIGURE 5—*Staphylococcus* cell-free media differentially impacts keratinocyte function**

686 Box plots showing effects of *Staphylococcus* cell-free conditioned-media on MTT (A, C, E) and  
687 TEER (B, D, F) assays, faceted by groups and colored by species. A & B show the MTT and  
688 TEER data, respectively, at the group-level (ie all isolates in the control group are pooled, as are  
689 all in the lesional and non-lesional groups). C & D show the MTT and TEER at species-level  
690 resolution. E & F illustrate MTT and TEER with each individual strain. Bonferroni adjusted p-  
691 value symbols: + 0.15, . 0.1, \* 0.05, \*\* 0.01, \*\*\*0.001, \*\*\*\* 0.0001

692

## 693 **Supplemental Methods**

### 694 **Patient recruitment and classification**

695 Food allergy was diagnosed by a board certified pediatric-allergist immunologist with typical  
696 signs and symptoms of immediate Ig-E mediated reaction (ex: hives, angioedema, vomiting, *etc.*)  
697 together with evidence of allergic sensitization or oral food challenge as previously described<sup>61</sup>.  
698 Other allergic disease diagnosis was determined by parental report of physician diagnosis and  
699 confirmed by medical record review.

700

### 701 **Sample collection**

702 Swabs were obtained from the forearm by rolling the swab with moderate pressure 10 times over  
703 the designated area, and then by turning the swab 90 degrees and rolling the swab 10 additional  
704 times. Lesional swabs were collected from sites of active lesions and nonlesional swabs were  
705 obtained from healthy-appearing skin from a similar body site (for example, just adjacent to the  
706 lesion, or on the contralateral body site) in a similar fashion, or from the anterior forearm when  
707 no lesion was present. Swabs were then submerged in lysis buffer and stored at -80 °C for further  
708 analysis.

709

### 710 **Bacterial isolation**

711 Samples were thawed and 100 µL were pipetted onto 4 media plates—brain heart infusion (BHI)  
712 agar, BHI + 0.1% Tween 80 (BHIT) agar, blood agar, and mannitol salt agar. Glass beads were  
713 used to spread the sample evenly across plates. After the beads were removed and the plates  
714 dried, they were incubated at 28 °C for 2-3 days. At this time, morphologically unique colonies  
715 were picked from the plates and streaked for isolation onto fresh plates of the same media type.  
716 All plates were then returned to the 28 °C incubator. Every 2-3 days for 1 week, the original  
717 culture plates were checked for new colonies. An individual colony was picked from the pure  
718 cultures on the isolation plates and grown in BHIT liquid culture overnight at 37 °C. After the  
719 cultures were turbid, a 15% glycerol stock was prepared for storage at -80 °C.

720

721 Bacterial isolates from stock were grown on BHIT agar overnight at 37 °C. From these plates,  
722 one colony was inoculated into 3 mL liquid BHI + (0.1%) Tween and incubated with shaking at  
723 37 °C overnight. The 16S rRNA gene was amplified using PCR. Briefly, 0.5 µL of the overnight  
724 culture was added to 24.5 µL of master mix (12.5 µL Econotaq PLUS green, 1 µL F primer 16S  
725 8F (10 µM), 1 µL R Primer 16S 1492R (10 µM), 10 µL nuclease free water) and run on a  
726 thermocycler (95 °C for 10 min, [95 °C for 30 s, 54 °C for 30 s, 72 °C for 60 s] for 30 cycles, 72  
727 °C for 5 min, hold at 4 °C). Product was confirmed by running on a 1% agarose gel and then sent  
728 for Sanger sequencing at Functional Biosciences, Inc (Madison, WI).

729

### 730 **Generation of staphylococcal cell free supernatants**

731 Supplemented keratinocyte growth media was composed of 500 mL Medium 154 (Life  
732 Technologies), 500 mL Keratinocyte Serum Free Media with calcium (Life Technologies), 5 mL  
733 Human Keratinocyte Growth Serum (Life Technologies), 25 mg bovine pituitary extract (Life  
734 Technologies), 0.0025 mg human recombinant epidermal growth factor (Life Technologies), 50  
735 mg/mL L-proline (DOT Scientific Inc), 15 mg/mL nicotinic acid (DOT Scientific Inc), and 2  
736 mg/mL pantothenic acid (VWR)<sup>21,62,63</sup>.

737

### 738 **Metagenomic library preparation and analysis**

739 Samples were processed at University of Minnesota Genomics Center (UMGC) for library  
740 preparation using the Nextera XT DNA Library Prep kit (Illumina), and metagenomic  
741 sequencing on a NovaSeq (Illumina 2 x 150 bp reads). Resulting FASTQ files were processed  
742 using quality filtering, adapter removal, human decontamination, and tandem repeat removal as  
743 described previously<sup>40</sup>. Taxonomic classification and abundance estimation was performed using  
744 Kraken2 (v2.0.8-beta)<sup>41</sup> and Bracken (v2.5)<sup>42</sup>. A custom Kraken2 database was used as described  
745 previously<sup>40</sup>, with the addition of 165 novel skin genomes from Saheb Kashaf *et al.*<sup>64</sup>. Reads  
746 assigned as *Homo sapiens* or that were unclassified at the genus level were filtered out.  
747 Decontam (v1.16.0) was then used to identify and remove contaminant reads using the  
748 “prevalence” method, based on negative controls collected at time of swab collection and  
749 processed with samples. See Supplemental Figure 2 for read counts at each step.

750

### 751 **MTT assay**

752 Cell viability was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium  
753 bromide (MTT) colorimetric assay (Roche Diagnostics, Mannheim, Germany) per manufacturer  
754 instructions. For the MTT assay, 10,000 neonatal human keratinocyte (HK; obtained from  
755 American Type Culture Collection (ATCC, Manassas, Virginia) cells were plated into a 96-well  
756 plate and cultured in a 5% CO<sub>2</sub> atmosphere at 37 °C. To determine the effect of the  
757 *Staphylococcus* supernatants on HK cell viability, the cells were treated with HK media alone  
758 (154 Human keratinocyte media (Thermo Fisher Scientific) supplemented with Human  
759 Keratinocyte Growth Supplement and penicillin/streptomycin (Thermo Fischer Scientific)  
760 additives) or HK media containing one of the *Staphylococcus* supernatants for 48 hours. The  
761 concentration of all supernatant treatments was standardized to 1\*10<sup>6</sup> CFU/mL. After the  
762 treatment period, HK were incubated in an MTT solution for 4 hours. A solubilization buffer was  
763 then added to each well and the cells were incubated in a humidified atmosphere at 37°C  
764 overnight. The absorbance was measured at 550 to 600 nm, with a reference wavelength of >650  
765 nm, using a microplate reader (BioTek). The absorbance values were then used to determine cell  
766 viability.

767

768

769

770 **SUPPLEMENTAL TABLE 1**

771 Table showing the medication usage and allergic co-morbidities of all subjects. AD = atopic  
772 dermatitis; FA = food allergy; F = female; M = male; N = no; Y = yes; \* = irritant contact  
773 dermatitis.

774

775

776 **SUPPLEMENTAL TABLE 2**

777 Table depicting the number of isolates of each species collected from each participant.

778

779

780

781

782

783

784

785

786

787

788

789

790

791 **SUPPLEMENTAL FIGURE 1**

792 Diagram of the workflow.

793

794 **SUPPLEMENTAL FIGURE 2**

795 Count data at each filter step.

796

797 **SUPPLEMENTAL FIGURE 3**

798 Bar chart of the relative abundances of Eukaryotic (A) & Viral (B) species. Color and point

799 shape correspond to AD status. \*:  $p < 0.05$ , \*\*:  $p < 0.01$  **SUPPLEMENTAL FIGURE 4**

800 Bacterial Shannon Diversity Index broken out into evenness (A) & richness (B).



**Figure 1**









